Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

NEW YORK (AP) — U.S. stocks climbed further into record heights on Thursday after a report showed the U.S. job market looks ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which foods to avoid on a GLP-1 and how to prevent muscle loss.

Novo Nordisk A/S struck a deal with WeightWatchers to boost access to its Wegovy obesity drug, just days after axing a collaboration with telehealth company Hims & Hers Health Inc. WeightWatchers ...

VK2375 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly 's blockbuster weight loss drug Zepbound. Viking is developing VK2375 in both subcutaneous (under the skin) and oral formulations.